NOTICE OF ANNUAL GENERAL MEETING IN XINTELA AB (PUBL)
The shareholders of Xintela AB (publ) are invited to the annual general meeting on Friday, May 6 2022, at 09.00 CET at Medicon Village, Scheeletorget 1, Building 601 Lund, Sweden. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. […]
Xintela AB Year-end report January – December 2021
Summary of the year end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter October 1 – December 31, 2021Income amounted to TSEK 0 (0).Loss before tax totalled TSEK 26,643 (loss: 25,335).Loss per share* was SEK 0.30 (loss: 0.34).At December 31, 2021, the equity/assets ratio** was 16% (57). […]
New board of directors appointed in Targinta AB
Xintela AB announces the appointment of a new board of directors in Targinta AB, a wholly-owned subsidiary of Xintela. Jeffrey Abbey, Karin Wingstrand and Maarten de Château have been appointed as new board members. Gregory Batcheller, chairman, and Evy Lundgren-Åkerlund are already members of the board of Targinta. Gunnar Telhammar resigns as board member. The […]
Xintela to develop stem cell therapy for difficult-to-heal wounds
Xintela announces today that the company will develop its stem cell product XSTEM® for the treatment of difficult-to-heal (chronic) wounds. In collaboration with The Burn Center at Linköping University Hospital, Xintela has found that XSTEM has excellent wound healing capability in a preclinical model and is now planning for a clinical trial on patients with […]
Targinta recruits Per Norlén as CEO
Lund, Sweden, May 4, 2021 – Xintela announces today that Per Norlén has been recruited as CEO of Xintela’s wholly owned oncology subsidiary Targinta. He will start on 1 September 2021. Per Norlén will also have the role of Xintela’s Chief Medical Officer (CMO) from 1 July 2021. The recruitment is an important step in […]
Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK
Lund, Sweden, 6 April 2021 – Xintela today announces the positive outcome of the preclinical ARDS (Acute Respiratory Distress Syndrome) study partly financed by Vinnova. The results of the study demonstrate the potential of the company’s stem cell product XSTEM® in the treatment of ARDS, a life-threatening lung complication that can affect severely ill COVID-19 […]
Xintela gets tissue establishment license
Lund, Sweden, 19 March 2021 – Xintela announces today that the company has received a tissue establishment license from the Swedish Medical Products Agency for handling human tissues and cells for manufacturing medicinal products. In order to conduct activities that use human tissues and cells for the manufacture of medicinal products, a tissue establishment license […]
Xintela submits manufacturing license application
Lund, Sweden, 21 December 2020 – Xintela announces today that the company has submitted its application to the Swedish Medical Products Agency for a license to produce cell therapy products, also known as Advanced Therapy Medicinal Products (ATMPs), for clinical studies. Xintela has developed and patented the stem cell product platform XSTEM® and built its […]
Xintela recruits Jeffrey Abbey to Targinta
Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Mr. Abbey has more than 20 years of experience in the biopharmaceutical industry and has spent much of his career focused on the development of […]
Xintela expands and strengthens management team
Lund, Sweden, August 19, 2020 – Xintela announces it is expanding and strengthening its management team with Peter Ekolind as COO (Chief Operating Officer) and Thomas Areschoug as CBO (Chief Business Officer). Sven Kili, who has had a combined role as COO and CMO (Chief Medical Officer), will focus on his role as CMO. “As […]
